EGFR and non-small cell lung carcinoma: recently published a correlation analysis of 57 EGFRm NSCLC patients who received ICI treatment after developing PD on EGFR TKIs (94).They identified by using a TKI-PFS cutoff of 10 months that EGFRm patients with <10 month TKI-PFS had significantly improved ICI-PFS of 15.1 versus 3.8 months, respectively (HR 0.26, 95% CI: 0.12-0.5, p = 0.0002), strongly suggesting that EGFRm tumors are either TKI or ICI responsive.